These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38613425)

  • 1. Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.
    Peyrin-Biroulet L; Dubinsky MC; Sands BE; Panés J; Schreiber S; Reinisch W; Feagan BG; Danese S; Yarur AJ; D'Haens GR; Goetsch M; Wosik K; Keating M; Lazin K; Wu J; Modesto I; McDonnell A; Bartolome L; Vermeire S
    J Crohns Colitis; 2024 Aug; 18(8):1270-1282. PubMed ID: 38613425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
    Sandborn WJ; Vermeire S; Peyrin-Biroulet L; Dubinsky MC; Panes J; Yarur A; Ritter T; Baert F; Schreiber S; Sloan S; Cataldi F; Shan K; Rabbat CJ; Chiorean M; Wolf DC; Sands BE; D'Haens G; Danese S; Goetsch M; Feagan BG
    Lancet; 2023 Apr; 401(10383):1159-1171. PubMed ID: 36871574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12.
    Armuzzi A; Rubin DT; Schreiber S; Panés J; Fellmann M; Bartolome L; Gruben D; Goetsch M; Bhattacharjee A; Chaparro M; Dubinsky MC
    Inflamm Bowel Dis; 2024 Sep; ():. PubMed ID: 39326009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Etrasimod in Patients with Ulcerative Colitis in Japan: Data from the Phase 3 ELEVATE UC 12 and ELEVATE UC 40 JAPAN Trials.
    Takeuchi K; Hisamatsu T; Nakase H; Matsuoka K; Keating M; Yuasa H; Oe M; Arai S; Mazur R; Hibi T
    Digestion; 2024 Sep; ():1-9. PubMed ID: 39317165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial.
    Yarur AJ; Chiorean MV; Panés J; Jairath V; Zhang J; Rabbat CJ; Sandborn WJ; Vermeire S; Peyrin-Biroulet L
    J Crohns Colitis; 2024 Jun; 18(6):885-894. PubMed ID: 38245818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With Etrasimod.
    Magro F; Peyrin-Biroulet L; Sands BE; Danese S; Jairath V; Goetsch M; Bhattacharjee A; Wu J; Branquinho D; Modesto I; Feagan BG
    Clin Gastroenterol Hepatol; 2024 Jul; ():. PubMed ID: 39089519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme.
    Regueiro M; Siegmund B; Yarur AJ; Steinwurz F; Gecse KB; Goetsch M; Bhattacharjee A; Wu J; Green J; McDonnell A; Crosby C; Lazin K; Branquinho D; Modesto I; Abreu MT
    J Crohns Colitis; 2024 Oct; 18(10):1596-1605. PubMed ID: 38700040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Peyrin-Biroulet L; Zhang J; Chiorean M; Vermeire S; Lee SD; Kühbacher T; Yacyshyn B; Cabell CH; Naik SU; Klassen P; Panés J
    Gastroenterology; 2020 Feb; 158(3):550-561. PubMed ID: 31711921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etrasimod Corticosteroid-Free Efficacy, Impact of Concomitant Corticosteroids on Efficacy and Safety, and Corticosteroid-Sparing Effect in UC: Analyses of the ELEVATE UC Clinical Programme.
    Sands BE; Leung Y; Rubin DT; Gecse KB; Panés J; Goetsch M; Wang W; Woolcott JC; Smith CC; Wosik K; Schreiber S
    J Crohns Colitis; 2024 Sep; ():. PubMed ID: 39306680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etrasimod: A Sphingosine-1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis.
    Choi D; Becker M; Ivanov M; Bhat S
    Ann Pharmacother; 2024 Oct; 58(10):1054-1063. PubMed ID: 38258760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials.
    Vermeire S; Sands BE; Peyrin-Biroulet L; D'Haens GR; Panés J; Yarur AJ; Wolf DC; Ritter T; Schreiber S; Woolcott JC; Modesto I; Keating M; Shan K; Wu J; Chiorean MV; Baert F; Dubinsky MC; Goetsch M; Danese S; Feagan BG
    J Crohns Colitis; 2024 Nov; 18(11):1780-1794. PubMed ID: 38877972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program.
    Jairath V; Rubin DT; Verstockt B; Çekin AH; Abreu MT; Lees CW; Fellmann M; Woolcott JC; Crosby C; Wu J; Bhattacharjee A; Herman D; Gu G; Siegmund B
    Inflamm Bowel Dis; 2024 Jun; ():. PubMed ID: 38899786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study.
    Vermeire S; Chiorean M; Panés J; Peyrin-Biroulet L; Zhang J; Sands BE; Lazin K; Klassen P; Naik SU; Cabell CH; Sandborn WJ
    J Crohns Colitis; 2021 Jun; 15(6):950-959. PubMed ID: 33475734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial.
    Kruis W; Siegmund B; Lesniakowski K; Simanenkov V; Khimion L; Sobon M; Delmans G; Maksyashina SV; Sablin OA; Pokrotnieks J; Mostovoy Y; Datsenko O; Abdulkhakov S; Dorofeyev A; Levchenko O; Alexeeva O; Andreev P; Kolesnik IP; Mihaly E; Abrahamovych O; Baluta M; Kharchenko N; Viacheslav N; Uspenskiy Y; Vieth M; Mohrbacher R; Mueller R; Greinwald R
    J Crohns Colitis; 2022 Nov; 16(11):1714-1724. PubMed ID: 35709376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
    Rubin DT; Dotan I; DuVall A; Bouhnik Y; Radford-Smith G; Higgins PDR; Mishkin DS; Arrisi P; Scalori A; Oh YS; Tole S; Chai A; Chamberlain-James K; Lacey S; McBride J; Panés J;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):17-27. PubMed ID: 34798036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
    Bosworth BP; Sandborn WJ; Rubin DT; Harper JR
    Inflamm Bowel Dis; 2016 Aug; 22(8):1881-6. PubMed ID: 27416045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
    Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
    Danese S; Vermeire S; Zhou W; Pangan AL; Siffledeen J; Greenbloom S; Hébuterne X; D'Haens G; Nakase H; Panés J; Higgins PDR; Juillerat P; Lindsay JO; Loftus EV; Sandborn WJ; Reinisch W; Chen MH; Sanchez Gonzalez Y; Huang B; Xie W; Liu J; Weinreich MA; Panaccione R
    Lancet; 2022 Jun; 399(10341):2113-2128. PubMed ID: 35644166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the S1PR modulator etrasimod in the treatment of moderately to severely active ulcerative colitis during the induction phase: a systematic review and meta-analysis of randomized controlled trials.
    Qiu J; Liu J; Cai K; Xu T; Liu W; Lin F; Shi N
    Front Pharmacol; 2024; 15():1420455. PubMed ID: 39314756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.